News and Trends 8 Jun 2020 UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood A seed round of €10.1M will fund the launch of the University of Oxford spinout Base Genomics, which aims to improve cancer detection by measuring epigenetic changes to tumor DNA circulating in the blood. The company’s oversubscribed seed funding round was led by Oxford Sciences Innovation, a local early-stage investment firm linked to the University […] June 8, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
Sponsored by PCMG 8 Jun 2020 Why Biotechs Should Invest in Good Outsourcing Management of CROs The relationship between biotechs and their CRO partners has been long in the making. These days, a collaboration with CROs is seen as a standard in the drug development industry. However, the management of drug development partners and providers can be highly challenging for biotechs. This is where outsourcing expertise can make the difference between […] June 8, 2020 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 8 Jun 2020 Regulations on Genetic Data Could Threaten Genomics Innovation As genetic research relies more and more on digital technology, international regulations are straining to catch up and some fear they threaten to stifle innovation. Is it possible to develop a regulatory framework for genetic data that is fair for everyone? In just a couple decades, the digital revolution has taken over all sorts of […] June 8, 2020 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2020 Boost For Inflammatory Disease Biotech NodThera With €49M Series B The UK-US biotech NodThera has raised €48.7M in Series B funding to progress its drug candidate through clinical trials for the treatment of inflammatory conditions such as inflammatory bowel disease. This round follows an impressive €32M Series A that Nodthera carried out in 2018. Danish firm Novo Ventures, part of the investment arm of Novo […] June 6, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2020 Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug Swedish company Calliditas Therapeutics has raised an €80M IPO on the Nasdaq Global Select Market — 20% above its initial target — to fund an ongoing phase III trial of its lead candidate treatment for an inflammatory kidney condition. Calliditas plans to use the net proceeds together with its existing cash resources to fund an […] June 5, 2020 - 2 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2020 Israeli-Dutch Biotech Raises €55M to Fight Huntington’s Disease and ALS Prilenia Therapeutics has raised €55M in Series A funding to launch late-stage clinical trials of its small molecule candidate drug in Huntington’s disease and amyotrophic lateral sclerosis, incurable conditions that have very limited treatment options. Dutch life sciences VC Forbion led the round and was joined by new Chinese investor Morningside Venture Investments and the […] June 5, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2020 Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate a fifth patent regarding the same technology. So far, Regeneron has not requested a re-hearing from the Board regarding the decision to uphold Kymab’s first […] June 4, 2020 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Expert Advice 4 Jun 2020 The Beginner’s Guide to Biotech & Life Science Marketing As life science professionals, we not only continuously handle hard science and research, but we also have to learn how to market our products and interact with a large online audience. However, coming from the sciences, many of us struggle with bio-business. Here is where you can start. In this article, we will take you […] June 4, 2020 - 13 minutesmins - By Letícia Manosso Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jun 2020 What Did European Oncology Players Offer at ASCO 2020? Despite widespread clinical trial delays caused by the coronavirus pandemic, many oncology biotechs have been able to continue their fight against cancer. With advances in CAR T-cell therapies, cancer vaccines, RNA drugs, and more, European companies held a strong presence at the American Society of Clinical Oncology (ASCO) this year. The huge ASCO conference has […] June 3, 2020 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Jun 2020 How Personal Genomics Companies Are Changing Drug Development In recent years, companies offering direct-to-consumer genomics tests have started switching the business model and venturing into drug development. Amidst criticism on data protection and lack of transparency, personal genomics companies are leveraging their unique position to generate genomics data to strike lucrative deals with pharma companies. Thanks to cheaper data acquisition and convenient analysis, […] June 1, 2020 - 6 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 AI Drug Discovery Firm Exscientia Closes €54M Series C UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The Danish investor Novo Holdings led the round with its first investment in the company. Additional funding also came from existing investors including drug development company Evotec and Chinese VC firm GT […] May 29, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 Argenx Follows up Phase III Success with Giant €785M Global Offering The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […] May 29, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email